The cardiovascular system medicine market in Canada is forecasted to decline steadily from $2.41 billion in 2024 to $1.81 billion by 2028. This downward trend highlights a significant year-over-year decrease in sales, which may reflect shifting market conditions, evolving healthcare priorities, or increased competition from generics.

Future trends to watch for include:

Innovations in cardiovascular treatments, potentially affecting sales volumes.
Healthcare policy changes that could impact drug pricing and availability.
Emerging competition from new therapeutic approaches affecting mainstream sales.